1. Home
  2. NUKK vs ACRV Comparison

NUKK vs ACRV Comparison

Compare NUKK & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nukkleus Inc.

NUKK

Nukkleus Inc.

HOLD

Current Price

$5.12

Market Cap

100.0M

Sector

Finance

ML Signal

HOLD

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

HOLD

Current Price

$2.55

Market Cap

82.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUKK
ACRV
Founded
2013
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Blank Checks
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
100.0M
82.7M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
NUKK
ACRV
Price
$5.12
$2.55
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$14.67
AVG Volume (30 Days)
1.6M
531.8K
Earning Date
11-14-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$805.20
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.34
$1.05
52 Week High
$78.32
$8.00

Technical Indicators

Market Signals
Indicator
NUKK
ACRV
Relative Strength Index (RSI) 42.17 59.35
Support Level $5.89 $2.44
Resistance Level $7.44 $2.73
Average True Range (ATR) 0.87 0.18
MACD -0.00 0.01
Stochastic Oscillator 14.10 65.79

Price Performance

Historical Comparison
NUKK
ACRV

About NUKK Nukkleus Inc.

Nukkleus Inc is a financial technology company that is focused on providing software and technology solutions. The company's operating segment includes General support services and Financial services. General support services include providing software, technology, customer sales and marketing, and risk management technology hardware and software solutions package under a GSA to a related party. Financial services include providing payment services from one fiat currency to another or to digital assets. It generates maximum revenue from the General support services segment. Geographically operates in USA, UK and Malta, with majority of revenue from United Kingdom (UK).

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Share on Social Networks: